Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xbrane And Stada’s Ranibizumab Snapped Up In North America

Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada

Executive Summary

Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.

You may also be interested in...



Ranibizumab Developer Xbrane Renegotiates IP Agreement In Landmark Year

With plans to obtain EU and US marketing authorizations for its Xlucane ranibizumab biosimilar, Xbrane has renegotiated a pre-existing intellectual property licensing agreement with Vaxiion Therapeutics, including the payment of royalties through February 2024.

US Biosimilars See A Banner Year Despite Few Approvals

With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.

Samsung Bioepis First To File EU Lucentis Rival

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel